Dopamine transporter single photon emission computerized tomography in the diagnosis of dementia with Lewy bodies
Abstract
Dementia with Lewy bodies (DLB) is part of the spectrum of Lewy body disorders. However, it may be difficult to diagnose patients who have dementia but no Parkinsonism. Visual and semiquantitative assessment of the nigrostriatal dopaminergic nerve terminals in the putamen and caudate nuclei can be obtained with single photon emission computerized tomography (SPECT) using ligands that bind to the dopamine transporter molecule in the membranes of the nigrostriatal nerve terminals. This can be employed as a means of identifying subclinical degeneration of nigrostriatal neurones in patients with suspected DLB, increasing the probability of the diagnosis. In several studies, the sensitivity and specificity of abnormal dopamine transporter scans with regard to diagnosing probable DLB are better than 75 and 90%, respectively. This communication outlines the evidence for this and discusses some of the advantages, potential disadvantages, and areas of uncertainty with regard to the use of dopamine transporter SPECT in DLB diagnosis. © 2009 Movement Disorder Society
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
FP-CIT SPECT and MIBG are indicative biomarkers in the current International Consensus diagnostic criteria for DLB.
“Brain dopamine transporter imaging using 123I-Ioflupane (FP-CIT) SPECT and cardiac sympathetic nerve imaging using 131I-Metaiodobenzylguanidine myocardial scintigraphy (MIBG) are well established markers for the diagnosis of DLB with high sensitivity and specificity and both are indicative biomarkers as part of the current International Consensus diagnostic criteria for DLB [21, 144–146].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [146]
FP-CIT SPECT and MIBG are well-established markers for diagnosis of DLB with high sensitivity and specificity.
“Brain dopamine transporter imaging using 123I-Ioflupane (FP-CIT) SPECT and cardiac sympathetic nerve imaging using 131I-Metaiodobenzylguanidine myocardial scintigraphy (MIBG) are well established markers for the diagnosis of DLB with high sensitivity and specificity and both are indicative biomarkers as part of the current International Consensus diagnostic criteria for DLB [21, 144–146].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [146]
Cites
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · see citing works
The use of neuroimaging techniques in the early and differential diagnosis of dementia
Chouliaras, L., & O’Brien, J. T. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02215-8 · Cited by 186 · see citing works
“…imaging using 131 I-Metaiodobenzylguanidine myocardial scintigraphy (MIBG) are well established markers for the diagnosis of DLB with high sensitivity and speci fi city and both are indicative biomarkers as part of the current International Consensus diagnostic criteria for DLB [21, 144 – 146].”
BackgroundParkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation
Tanaka, M. (2025) · doi:10.20944/preprints202506.2099.v2 · Cited by 57 · see citing works
- Authors
- Walker, R. W. H., & Walker, Z.
- Affiliations
- National Health Service (GB)
- University College London (GB)
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2009-01
- Volume
- 24
- Issue
- S2
- Pages
- S754-9
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W1998391868
- Cited by
- 86
- References
- 1
- Citations by year
- 2025: 3 · 2024: 4 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 33 · 2019: 4 · 2018: 7 · 2017: 3 · 2016: 2 · 2015: 5 · 2014: 2 · 2013: 4 · 2012: 4
- FWCI
- 0.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Movement Disorders (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- dementia with Lewy bodies, dopamine transporter SPECT, nigrostriatal dopaminergic neurons, Lewy body disease, sensitivity and specificity, putamen, caudate nucleus, neuroimaging diagnosis
- MeSH terms
- Autopsy, Humans, Neuropsychological Tests, Substantia Nigra, Tomography, Emission-Computed, Single-Photon, Neostriatum, Lewy Body Disease, Dopamine Plasma Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
